PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Massimiliano Berretta(University of Messina), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Laura Canale(Ospedale Versilia), Vienna Giordano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 42
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105